Gilead Sciences CDR (CAD Hedged) (GILD : TSX)
Common Stock
$27.56
CAD
+0.91 (3.41%)
Last updated: 2026-07-16
GILD
Gilead Sciences CDR (CAD Hedged)
WealthAwesomePerformance
1 Day
+3.41%
1 Week
+0.92%
1 Month
+9.41%
YTD
+10.59%
Key Statistics
Market Cap
$174.33B
52W High
$31.41
52W Low
$21.88
P/E Ratio
17.32
50 Day MA
$26.36
200 Day MA
$27.64
Beta
-
Dividend Yield
11.57%
Technical Indicators
Price vs 50-Day SMA
Price vs 200-Day SMA
Recent Price History
| Date | Open | High | Low | Close | Adj Close | Volume |
|---|---|---|---|---|---|---|
| 7/16/2026 | $26.84 | $27.56 | $26.84 | $27.56 | $27.56 | 24,259 |
| 7/15/2026 | $26.39 | $26.65 | $26.39 | $26.65 | $26.65 | 9,553 |
| 7/14/2026 | $26.33 | $26.50 | $26.33 | $26.39 | $26.39 | 3,300 |
| 7/13/2026 | $25.95 | $26.63 | $25.95 | $26.61 | $26.61 | 7,298 |
| 7/10/2026 | $27.48 | $27.48 | $26.27 | $26.27 | $26.27 | 8,757 |
| 7/9/2026 | $27.52 | $27.52 | $27.07 | $27.31 | $27.31 | 2,495 |
| 7/8/2026 | $27.76 | $27.76 | $27.36 | $27.54 | $27.54 | 7,351 |
| 7/7/2026 | $26.59 | $27.63 | $26.59 | $27.63 | $27.63 | 8,194 |
| 7/6/2026 | $27.06 | $27.06 | $25.96 | $26.26 | $26.26 | 7,855 |
| 7/3/2026 | $27.03 | $27.03 | $26.95 | $26.95 | $26.95 | 1,365 |
Wealth Awesome Price Forecast
WA ModelStatistical 90-day price range based on GILD's historical volatility
30-Day Vol
33.3%
Annualized
90-Day Vol
27.8%
Annualized
Trend (90d)
-7.4%
Annualized drift
90d Mean
C$26.84
Expected price
| Horizon | Expected | 68% Range (1σ) |
|---|---|---|
| 30 trading days | C$27.32 | C$24.36 – C$30.64 |
| 60 trading days | C$27.08 | C$23.02 – C$31.85 |
| 90 trading days | C$26.84 | C$22.00 – C$32.75 |
Methodology: Range is calculated using 30-day realized volatility via geometric Brownian motion (log-normal model). 68% band = ±1σ, 95% band = ±2σ. This is a statistical model, not a prediction. Past volatility does not guarantee future results. Not financial advice.
About Gilead Sciences CDR (CAD Hedged)
Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis. It also offers Yescarta, Tecartus, and Trodelvy products for the treatment of oncology; Letairis, an oral formulation for the treatment of pulmonary arterial hypertension; and AmBisome, a liposomal formulation for the treatment of serious invasive fungal infections. The company has collaboration agreements with Arcus Biosciences, Inc.; Merck Sharp & Dohme Corp.; Pionyr Immunotherapeutics Inc.; Tizona Therapeutics, Inc.; Galapagos NV; Janssen Sciences Ireland Unlimited Company; Japan Tobacco, Inc.; Dragonfly Therapeutics, Inc.; Arcellx, Inc.; Everest Medicines; Merck & Co, Inc.; Tentarix Biotherapeutics Inc.; Marengo Therapeutics; and Assembly Biosciences, Inc. It also has research collaboration, option, and license agreement with Merus N.V. for the discovery of novel dual tumor-associated antigens (TAA) targeting trispecific antibodies. The company has a collaboration with Terray Therapeutics, Inc. to discover and develop small molecule therapies; and LEO Pharma to develop, manufacture, and commercialize the small molecule oral STAT6 program. The company was incorporated in 1987 and is headquartered in Foster City, California.
Financials
- Revenue (TTM)
- $0
- EBITDA
- -
- Profit Margin
- 0.00%
- ROE (TTM)
- 4049.30%
- EPS (Diluted)
- 0.00
- Book Value
- -
💰 Recent Dividends
$0.1670
Ex: Mar 13, 2026
$0.1601
Ex: Dec 15, 2025
$0.1633
Ex: Sep 15, 2025
$0.1640
Ex: Jun 13, 2025
Advertisement
7 stocks to buy and hold forever
Blue-chip dividend stocks for long-term wealth building.
Get the FREE Report